Daniel Fierer, MD
Infectious Disease · New York, NYNPI 1649298472
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Cumberland Pharmaceuticals, Inc.. That places this record below the midpoint for infectious disease clinicians in NY, where the typical reported total is $190.
Across 1 payment — averaging $21.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cumberland Pharmaceuticals, Inc.$21
Across 14 payments — averaging $36,669 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$285K
- Merck$229K
What the payments were for
- Food & beverage$21100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cumberland Pharmaceuticals, Inc. | 1 | $21 |
How this compares
$21 in reported general payments places this provider in the 20th percentile of 799 infectious disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 261 | $1,029,834 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 105 | $436,257 |
| TivicayDolutegravir Sodium | 173 | $435,393 |
| DescovyEmtricitabine/Tenofov Alafenam | 137 | $320,895 |
| RukobiaFostemsavir Tromethamine | 36 | $315,383 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 26 | $94,784 |
| DovatoDolutegravir Sodium/Lamivudine | 21 | $85,526 |
| IsentressRaltegravir Potassium | 31 | $60,734 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 13 | $57,130 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 13 | $49,269 |
| OzempicSemaglutide | 39 | $41,302 |
| PrezcobixDarunavir/Cobicistat | 15 | $37,217 |
| MounjaroTirzepatide | 25 | $32,533 |
| Isentress HdRaltegravir Potassium | 11 | $20,230 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 47 | $17,241 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in New York
- Sian JonesNew York$406K
- Antonio UrbinaNew York$373K
- David BekhorNew York$358K
- Genovefa PapanicolaouNew York$209K
- Michelle CespedesNew York$125K
- Donald KaminskyNew York$120K
- Judith AbergNew York$104K
- Thomas WalshNew York$98K
- Stuart HaberNew York$73K
- Michael GaisaNew York$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.